BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 21946058)

  • 1. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
    Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
    Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2.
    Binet F; Girard D
    J Leukoc Biol; 2008 Dec; 84(6):1613-22. PubMed ID: 18728151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38MAPK-Dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death.
    Myatt SS; Redfern CP; Burchill SA
    Clin Cancer Res; 2005 Apr; 11(8):3136-48. PubMed ID: 15837770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells.
    Kang YH; Lee SJ
    J Cell Physiol; 2008 Oct; 217(1):23-33. PubMed ID: 18412143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
    Giafis N; Katsoulidis E; Sassano A; Tallman MS; Higgins LS; Nebreda AR; Davis RJ; Platanias LC
    Cancer Res; 2006 Jul; 66(13):6763-71. PubMed ID: 16818652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.
    Maeda H; Hori S; Nishitoh H; Ichijo H; Ogawa O; Kakehi Y; Kakizuka A
    Cancer Res; 2001 Jul; 61(14):5432-40. PubMed ID: 11454688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of MAPK inhibitors on arsenic trioxide-treated Calu-6 lung cells in relation to cell death, ROS and GSH levels.
    Han YH; Moon HJ; You BR; Kim SZ; Kim SH; Park WH
    Anticancer Res; 2009 Oct; 29(10):3837-44. PubMed ID: 19846917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis.
    Ramos AM; Fernandez C; Amrán D; Esteban D; de Blas E; Palacios MA; Aller P
    J Cell Physiol; 2006 Dec; 209(3):1006-15. PubMed ID: 16972261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide concentration determines the fate of Ewing's sarcoma family tumors and neuroblastoma cells in vitro.
    Jung HS; Kim HS; Lee MJ; Shin HY; Ahn HS; Ryu KH; Seoh JY; Kim CJ; Jang JJ
    FEBS Lett; 2006 Sep; 580(20):4969-75. PubMed ID: 16930595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1beta induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-kappaB signaling pathways in human tracheal smooth muscle cells.
    Liang KC; Lee CW; Lin WN; Lin CC; Wu CB; Luo SF; Yang CM
    J Cell Physiol; 2007 Jun; 211(3):759-70. PubMed ID: 17311279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
    Kajiguchi T; Yamamoto K; Iida S; Ueda R; Emi N; Naoe T
    Cancer Sci; 2006 Jun; 97(6):540-5. PubMed ID: 16734734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel indoloquinoline derivative, IQDMA, induces G(2)/M phase arrest and apoptosis in A549 cells through JNK/p38 MAPK signaling activation.
    Su JC; Lin KL; Chien CM; Lu CM; Chen YL; Chang LS; Lin SR
    Life Sci; 2009 Sep; 85(13-14):505-16. PubMed ID: 19699753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS; Woo CW; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anisomycin induces apoptosis of glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells via activation of mitogen-activated protein kinases p38 and JNK.
    Liu Y; Ge J; Li Q; Gu L; Guo X; Ma ZG; Zhu YP
    Neoplasma; 2013; 60(1):101-10. PubMed ID: 23067223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p38 Mitogen-activated protein kinase and c-Jun NH2-terminal protein kinase regulate the accumulation of a tight junction protein, ZO-1, in cell-cell contacts in HaCaT cells.
    Minakami M; Kitagawa N; Iida H; Anan H; Inai T
    Tissue Cell; 2015 Feb; 47(1):1-9. PubMed ID: 25435485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
    Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
    J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bee venom suppresses PMA-mediated MMP-9 gene activation via JNK/p38 and NF-kappaB-dependent mechanisms.
    Cho HJ; Jeong YJ; Park KK; Park YY; Chung IK; Lee KG; Yeo JH; Han SM; Bae YS; Chang YC
    J Ethnopharmacol; 2010 Feb; 127(3):662-8. PubMed ID: 19969058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenyl N-tert-butylnitrone down-regulates interleukin-1 beta-stimulated matrix metalloproteinase-13 gene expression in human chondrocytes: suppression of c-Jun NH2-terminal kinase, p38-mitogen-activated protein kinase and activating protein-1.
    Ahmed S; Rahman A; Hasnain A; Goldberg VM; Haqqi TM
    J Pharmacol Exp Ther; 2003 Jun; 305(3):981-8. PubMed ID: 12626640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.
    Chen KT; Hour MJ; Tsai SC; Chung JG; Kuo SC; Lu CC; Chiu YJ; Chuang YH; Yang JS
    Int J Oncol; 2011 Sep; 39(3):611-9. PubMed ID: 21667022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.